Principal Financial Group’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
ACA
BI
SL
Principal Financial Group's KYMR Position: Q2 2026 in Review
Principal Financial Group increased its Kymera Therapeutics (KYMR) stake by 0.92% in Q2 2026, buying an estimated $3.27K and bringing the position to 4,185 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #2003.
Principal Financial Group first reported a position in KYMR in Q2 2021 and has held it in 16 quarters since. The position peaked at $760K in Q4 2021. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.
- Principal Financial Group held 4,185 shares of Kymera Therapeutics worth $480K as of Q2 2026.
- Principal Financial Group bought 38 Kymera Therapeutics shares in Q2 2026, an estimated $3.27K.
- Kymera Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2003 holding.
- Principal Financial Group first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 16 quarters since.
- Principal Financial Group's Kymera Therapeutics position peaked at $760K in Q4 2021.
- 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.
Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.